D. Boral Capital Reiterates "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $10.00 price objective on the stock. D. Boral Capital's price target would indicate a potential upside of 250.88% from the company's previous close.

Other equities analysts also recently issued reports about the company. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, March 25th. Maxim Group initiated coverage on Anixa Biosciences in a research note on Friday, March 21st. They issued a "buy" rating and a $10.00 price target for the company.

Anixa Biosciences Stock Up 7.5 %

ANIX stock traded up $0.20 during trading on Thursday, hitting $2.85. 56,715 shares of the company's stock traded hands, compared to its average volume of 96,708. The firm has a market capitalization of $91.76 million, a P/E ratio of -7.31 and a beta of 0.52. The business has a fifty day simple moving average of $2.91 and a two-hundred day simple moving average of $2.94. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). On average, equities research analysts predict that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Activity

In related news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction on Friday, January 17th. The shares were acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the transaction, the director now owns 922,334 shares in the company, valued at approximately $2,370,398.38. This trade represents a 1.10 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Amit Kumar bought 43,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average price of $2.23 per share, with a total value of $95,890.00. Following the completion of the purchase, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 75,289 shares of company stock valued at $177,021. Company insiders own 25.30% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in Anixa Biosciences during the 4th quarter worth approximately $26,000. Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences during the third quarter worth approximately $34,000. Renaissance Technologies LLC raised its stake in Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the last quarter. Prosperity Wealth Management Inc. purchased a new position in Anixa Biosciences in the 4th quarter valued at $54,000. Finally, Jane Street Group LLC acquired a new stake in Anixa Biosciences during the 4th quarter worth $67,000. Institutional investors and hedge funds own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.